Aurobindo reported the following consolidated numbers for its second quarter that ended 30 September 2022:

Operational revenue of INR57.4bn ($701.5m), a 3.4% drop from INR59.4bn in the second quarter of last year and a nearly 8% fall over the first quarter
Net profit was INR4.1bn, a whopping 41% decline year-on-year and 21% drop quarter-on-quarter
US business, at $331m, was down 17% year-on-year and 14% quarter-on-quarter
Oral solids revenue was $230m from $288m in Q2 FY22 and $262m in Q1 FY23
API revenues grew significantly to INR9.7bn from INR7.8bn in Q2 FY22 and INR9.1 in Q1 FY23
The company expects to launch about 40 products over the next 12 months

.

Two Of Aurobindo’s Europe Biosimilar Filings Stuck, Licenses Ryzneuta From Yifan Pharma

Could MHRA Approve Bevacizumab Biosimilar Minus Phase III Trial?